نمایش مختصر رکورد

dc.contributor.authorSasannezhad, Payamen_US
dc.contributor.authorGhabeli Juibari, Alien_US
dc.contributor.authorSadri, Kayvanen_US
dc.contributor.authorDabbagh Kakhki, Vahidrezaen_US
dc.contributor.authorSadeghi, Raminen_US
dc.contributor.authorSabour, Mahsaen_US
dc.contributor.authorAlizadeh, Hesamen_US
dc.date.accessioned1399-07-09T12:23:06Zfa_IR
dc.date.accessioned2020-09-30T12:23:06Z
dc.date.available1399-07-09T12:23:06Zfa_IR
dc.date.available2020-09-30T12:23:06Z
dc.date.issued2017-07-01en_US
dc.date.issued1396-04-10fa_IR
dc.date.submitted2017-04-23en_US
dc.date.submitted1396-02-03fa_IR
dc.identifier.citationSasannezhad, Payam, Ghabeli Juibari, Ali, Sadri, Kayvan, Dabbagh Kakhki, Vahidreza, Sadeghi, Ramin, Sabour, Mahsa, Alizadeh, Hesam. (2017). 99mTc-TRODAT-1 SPECT Imaging in Early and Late Onset Parkinson’s Disease. Asia Oceania Journal of Nuclear Medicine and Biology, 5(2), 119-125. doi: 10.22038/aojnmb.2017.8844en_US
dc.identifier.issn2322-5718
dc.identifier.issn2322-5726
dc.identifier.urihttps://dx.doi.org/10.22038/aojnmb.2017.8844
dc.identifier.urihttp://aojnmb.mums.ac.ir/article_8844.html
dc.identifier.urihttps://iranjournals.nlai.ir/handle/123456789/420968
dc.description.abstract<strong><em>Objective(s): </em></strong>99mTc-TRODAT-1, which binds to the dopamine transporter, could be used to image the dopaminergic system in diagnosis of Parkinson's disease (PD). PD can be classified into two groups: late onset Parkinson's disease (LOPD) and early onset Parkinson's disease (EOPD). In this study we tried to determine the TRODAT SPECT findings in EOPD as compared to LOPD.<br /><strong><em>Methods: </em></strong>Fifteen patients were studied. The diagnosis of PD was defined by clinical criteria based on UK Parkinson's Disease Society Brain Bank criteria. Six patients whose age at onset of PD were younger than 50 were defined as patients with EOPD and 9 patients with older than 50 years were defined as patients with LOPD. All patients underwent 99mTc-TRODAT Brain SPECT.<br /><strong><em>Results: </em></strong>There was a significant decrease of striatal 99mTc-TRODAT-1 (TRODAT) binding in PD patients in both EOPD and LOPD. No significant difference was noticed between EOPD and LOPD in disease stage and symptoms. In visual analysis, 20 (66.67%) caudate nucleuses had decreased tracer uptake while all 30 (100%) putamens had decreased or absent tracer uptake. No significant difference between EOPD and LOPD was noticed in visual analysis. Striatum, Caudate and Putamen uptake ratio to background were calculated. No significant difference was noticed between EOPD and LOPD in these ratios. However there was significant difference in visual analysis (tracer uptake) as well as in uptake ratio between putamen and caudate nucleuses in both groups (P=0.001). On the other word, we found more diminished uptake in putamen as compared the caudate. Frequency and severity of putamen involvement were much more than caudate.<br /><strong><em>Conclusion: </em></strong>99mTc-TRODAT-1 SPECT imaging showed lower presynaptical dopami-nergical terminals density in both EOPD and LOPD. There was no difference between EOPD and LOPD in TRODAT uptake. Putamen showed more involvement and more diminished TRODAT uptake.<br /><br />en_US
dc.format.extent718
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoen_US
dc.publisherAsia Oceania Federation of Nuclear Medicine & Biologyen_US
dc.relation.ispartofAsia Oceania Journal of Nuclear Medicine and Biologyen_US
dc.relation.isversionofhttps://dx.doi.org/10.22038/aojnmb.2017.8844
dc.subjectTc-99m-TRODAT-1en_US
dc.subjectParkinson's diseaseen_US
dc.subjectEarly onseten_US
dc.subjectLate onseten_US
dc.subjectdopamine transporteren_US
dc.subjectNeurologyen_US
dc.title99mTc-TRODAT-1 SPECT Imaging in Early and Late Onset Parkinson’s Diseaseen_US
dc.typeTexten_US
dc.typeOriginal Articleen_US
dc.contributor.departmentDepartment of Neurology, Mashhad University of Medical Sciences, Mashhad, Iranen_US
dc.contributor.departmentDepartment of Neurology, Mashhad University of Medical Sciences, Mashhad, Iranen_US
dc.contributor.departmentNuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iranen_US
dc.contributor.departmentNuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iranen_US
dc.contributor.departmentNuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iranen_US
dc.contributor.departmentNuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iranen_US
dc.contributor.departmentNuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iranen_US
dc.citation.volume5
dc.citation.issue2
dc.citation.spage119
dc.citation.epage125
nlai.contributor.orcid0000-0003-0491-4128
nlai.contributor.orcid0000-0002-1666-5440


فایل‌های این مورد

Thumbnail

این مورد در مجموعه‌های زیر وجود دارد:

نمایش مختصر رکورد